How does ephedrine act on the body?
Acts directly on alpha-Adrenergic receptor sites
Stimulates the release of norepinephrine
Acts directly on Beta-Adrenergic receptor sites
Stimulates the release of Dopamine
The Correct Answer is B
A) Acts directly on alpha-adrenergic receptor sites: Ephedrine does not act exclusively or directly on alpha-adrenergic receptors. While it can have some alpha-adrenergic effects, its primary mechanism is through the release of norepinephrine, which then activates both alpha and beta receptors. Therefore, this option is not entirely accurate for describing ephedrine's mode of action.
B) Stimulates the release of norepinephrine: Ephedrine primarily works by stimulating the release of norepinephrine from nerve terminals. The released norepinephrine then acts on both alpha and beta adrenergic receptors, leading to vasoconstriction (via alpha receptors) and increased heart rate and force of contraction (via beta receptors). This dual action helps raise blood pressure and improve cardiac output, making this the most accurate description of ephedrine's mechanism of action.
C) Acts directly on beta-adrenergic receptor sites: Although ephedrine does have beta-adrenergic effects (increasing heart rate and contractility), its primary mechanism is the indirect release of norepinephrine. It does not act directly on beta-receptors to the same extent as medications like isoproterenol. Therefore, while it does have beta-receptor activity, the main action is through norepinephrine release.
D) Stimulates the release of dopamine: Ephedrine does not primarily stimulate dopamine release. Dopamine release is more associated with drugs like levodopa or certain dopaminergic agents used in conditions like Parkinson’s disease. Ephedrine primarily affects norepinephrine and, to a lesser extent, acts on dopamine receptors, but it is not primarily a dopamine-releasing agent.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is D
Explanation
A) Increase in mental acuity: Beta-adrenergic blockers (beta-blockers) do not directly affect mental acuity. In fact, some beta-blockers may cause side effects like fatigue or drowsiness, which can affect mental sharpness. Beta-blockers primarily focus on cardiovascular effects, not cognitive function, making this an unlikely therapeutic goal for their use.
B) Slowing of gastrointestinal motility: Beta-blockers can reduce sympathetic nervous system activity, which may indirectly affect the gastrointestinal system. However, slowing gastrointestinal motility is not a primary therapeutic goal of beta-blocker therapy. The main action of beta-blockers is in the cardiovascular system, not in regulating GI function.
C) Decreased production in gastric acid: Beta-blockers do not significantly reduce gastric acid production. Medications such as proton pump inhibitors or H2 blockers are typically used for managing gastric acid production or reflux. Beta-blockers focus on reducing the workload of the heart and controlling blood pressure, not on acid secretion.
D) Reduction in the heart rate and blood pressure: The primary therapeutic effect of beta-blockers is the reduction of heart rate (negative chronotropic effect) and blood pressure (due to reduced cardiac output and inhibition of the sympathetic nervous system). This is especially beneficial for managing conditions like hypertension, heart failure, and arrhythmias. It is the most likely goal of beta-blocker therapy prescribed by the provider.
Correct Answer is A
Explanation
A) Celecoxib (Celebrex):
Celecoxib is a selective COX-2 inhibitor that targets the cyclooxygenase-2 enzyme, which is primarily responsible for inflammation, pain, and fever. COX-2 inhibitors tend to cause less gastrointestinal irritation compared to nonselective NSAIDs like aspirin, which block both COX-1 and COX-2 enzymes. Because aspirin is causing gastrointestinal upset, switching to Celecoxib, which is less likely to irritate the stomach lining, may be an appropriate option to prevent myocardial infarction while minimizing gastrointestinal discomfort.
B) Enteric-coated aspirin:
Enteric-coated aspirin is designed to dissolve in the small intestine rather than the stomach, which may reduce some gastrointestinal irritation. However, it does not eliminate the risk entirely, and it still functions as a COX-1 inhibitor. If the patient is already experiencing gastrointestinal upset, simply switching to enteric-coated aspirin may not be sufficient to alleviate the discomfort, and other options should be considered.
C) Nabumetone (Relafen):
Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) with some COX-2 selectivity. While it may cause less gastrointestinal upset than non-selective NSAIDs like aspirin, it is still an NSAID and carries a risk of gastrointestinal side effects, especially with prolonged use.
D) A COX-2 inhibitor:
While COX-2 inhibitors, including Celecoxib, are typically effective in reducing inflammation and pain with fewer gastrointestinal side effects than traditional NSAIDs, the term "a COX-2 inhibitor" could refer to various drugs, and Celecoxib (Celebrex) is the most commonly used.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.